Citigroup
SGMT icon

Citigroup’s Sagimet Biosciences SGMT Stock Holding History

Citigroup’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
52,839
+39,253
+289% +$267K ﹤0.01% 3994
2026
Q1 		$71K Sell
13,586
-4,390
-24% -$24.5K ﹤0.01% 4397
2025
Q4 		$106K Buy
+17,976
New +$129K ﹤0.01% 4296
2025
Q3 		– Sell
-3,631
Closed -$27.7K – 6294
2025
Q2 		$27.7K Buy
+3,631
New +$15.3K ﹤0.01% 4999
2025
Q1 		– Sell
-111,208
Closed -$500K – 5918
2024
Q4 		$500K Sell
111,208
-5,522
-5% -$28K ﹤0.01% 3826
2024
Q3 		$323K Sell
116,730
-19,014
-14% -$58.6K ﹤0.01% 4027
2024
Q2 		$464K Buy
135,744
+130,735
+2,610% +$600K ﹤0.01% 3444
2024
Q1 		$27.1K Buy
5,009
+4,151
+484% +$29.8K ﹤0.01% 4931
2023
Q4 		$4.65K Buy
+858
New +$4.05K ﹤0.01% 5343

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citigroup's SGMT Position: Q2 2026 in Review

Citigroup increased its Sagimet Biosciences (SGMT) stake by 289% in Q2 2026, buying an estimated $267K and bringing the position to 52,839 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #3994.

Citigroup first reported a position in SGMT in Q4 2023 and has held it in 9 quarters since. The position peaked at $500K in Q4 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Citigroup held 52,839 shares of Sagimet Biosciences worth $408K as of Q2 2026.
  • Citigroup bought 39,253 Sagimet Biosciences shares in Q2 2026, an estimated $267K.
  • Sagimet Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3994 holding.
  • Citigroup first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 9 quarters since.
  • Citigroup's Sagimet Biosciences position peaked at $500K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.